SCHEMBL4200416

SCHEMBL4200416

Cc1cc([N+](=O)[O-])cc2c(=O)oc(=O)[nH]c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 5/20 0.39
TSHR P16473 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
GPR35 Q9HC97 1/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
NPC1 O15118 1/20 0.37
HSP90AA1 P07900 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP3A4 P08684 1/20 0.37
CA12 O43570 2/20 0.35
CA9 Q16790 2/20 0.35
EPHX2 P34913 1/20 0.35
PARP1 P09874 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11760932 0.83 ALDH1A1 (0.54) LMNAMAPTALDH1A1TSHRTDP1
SCHEMBL31433789 0.82 F7 (0.40) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL12501369 0.81 EPHX2 (0.41) SMN1; SMN2LMNAMAPTALDH1A1TSHR
SCHEMBL5280067 0.77 ABCB1 (0.46) SMN1; SMN2MAPTKMT2ACA12CA9
SCHEMBL17478972 0.76 SMN1; SMN2 (0.55) SMN1; SMN2LMNAMAPTALDH1A1TSHR
SCHEMBL1202256 0.76 GRIN2D (0.51) SMN1; SMN2LMNAMAPTALDH1A1TSHR
SCHEMBL30087001 0.74 LMNA (0.38) SMN1; SMN2LMNAMAPTTSHRMEN1
SCHEMBL3208633 0.74 GSK3B (0.38) LMNARAB9APARP1GRIN2DGRIN3B
SCHEMBL2906293 0.74 F2 (0.37) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL14698434 0.74 F2 (0.37) ALDH1A1PARP1GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116496248-A Synthesis method of cyantraniliprole impurity 江苏艾科姆检测有限公司 2023-07-28 CN claimed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 US disclosed
CN-116496248-A Synthesis method of cyantraniliprole impurity 江苏艾科姆检测有限公司 2023-07-28 CN disclosed
US-9556141-B2 Process for preparing N-substituted 1H-pyrazole-5-carboxylate compounds and derivatives thereof BASF SE (DE) 2017-01-31 US disclosed
US-9282741-B2 Aniline type compounds BASF SE (DE) 2016-03-15 US disclosed
EP-2782910-B1 PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLATE COMPOUNDS AND DERIVATIVES THEREOF BASF SE (DE) 2016-02-03 EP disclosed
US-20150250174-A1 USE OF N-THIO-ANTHRANILAMIDE COMPOUNDS ON CULTIVATED PLANTS BASF SE (DE) 2015-09-10 US disclosed
US-20150250173-A1 PESTICIDALLY ACTIVE MIXTURES COMPRISING ANTHRANILAMIDE COMPOUNDS BASF SE (DE) 2015-09-10 US disclosed
US-20150250175-A1 PESTICIDALLY ACTIVE MIXTURES COMPRISING ANTHRANILAMIDE COMPOUNDS BASF SE (DE) 2015-09-10 US disclosed
US-20150250172-A1 USE OF ANTHRANILAMIDE COMPOUNDS IN SOIL AND SEED TREATMENT APPLICATION METHODS BASF SE (DE) 2015-09-10 US disclosed
US-20050282868-A1 Substituted anthranilamides for controlling invertebrate pests E. I. DU PONT DE NEMOURS AND COMPANY 2005-12-22 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
WO-2005002627-A2 CONJUGATED COMPLEMENT CASCADE INHIBITORS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-01-13 WO disclosed
US-20050004031-A1 Conjugated complement cascade inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 US disclosed
EP-1417176-A1 SUBSTITUTED ANTHRANILAMIDES FOR CONTROLLING INVERTEBRATE PESTS E. I. du Pont de Nemours and Company (US) 2004-05-12 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed
WO-2003016284-A1 SUBSTITUTED ANTHRANILAMIDES FOR CONTROLLING INVERTEBRATE PESTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R SMN1; SMN2 934/4885LMNA 4410/4885MAPT 3296/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R SMN1; SMN2 1725/4885LMNA 4320/4885MAPT 2762/4885
US-20150250174-A1 USE OF N-THIO-ANTHRANILAMIDE COMPOUNDS ON CULTIVATED PLANTS NAT1, TST, NIT2 SMN1; SMN2 4588/4885LMNA 4139/4885MAPT 3117/4885
US-20150250173-A1 PESTICIDALLY ACTIVE MIXTURES COMPRISING ANTHRANILAMIDE COMPOUNDS AADAC, ARSA, SIRT7 SMN1; SMN2 2331/4885LMNA 4434/4885MAPT 3813/4885
US-20050282868-A1 Substituted anthranilamides for controlling invertebrate pests ANTXR2, PRXL2A, F9 SMN1; SMN2 2748/4885LMNA 3109/4885MAPT 4843/4885
US-20050004031-A1 Conjugated complement cascade inhibitors C9, CFH, CFB SMN1; SMN2 2736/4885LMNA 2162/4885MAPT 2992/4885
US-20150250175-A1 PESTICIDALLY ACTIVE MIXTURES COMPRISING ANTHRANILAMIDE COMPOUNDS MCU, AGK, MLYCD SMN1; SMN2 4665/4885LMNA 3904/4885MAPT 3497/4885
US-20150250172-A1 USE OF ANTHRANILAMIDE COMPOUNDS IN SOIL AND SEED TREATMENT APPLICATION METHODS HRH3, DDT, ANTXR2 SMN1; SMN2 3894/4885LMNA 3673/4885MAPT 3798/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 SMN1; SMN2 3736/4885LMNA 2907/4885MAPT 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.